Terumo Blood and Cell Technologies Autologous Biologics
Terumo Blood and Cell Technologies is a global leader in blood component, therapeutic apheresis, cellular and autologous biologic technologies. We believe in the potential of cells to do even more for patients than they do today. This belief inspires us to share our expertise in cell separation and collaborate with customers to advance the practice of autologous biologic technologies together.
We welcome the opportunity to help you navigate autologous biologics and find the products that best fit your needs as a clinician.
1Lohan P, Treacy O, Griffin M, Ritter T, Ryan A. Anti-donor immune responses elicited by allogeneic mesenchymal stem cells and their extracellular vesicles: are we still learning? Front Immunol. 2017;8:1626.
2Sivanathan K, Gronthos S, Rojas-Canales D, Thierry B, Coates P. Interferon-gamma modification of mesenchymal stem cells: implications of autologous and allogeneic mesenchymal stem cell therapy in allotransplantation. Stem Cell Reviews and Reports. 2014;10(3):351-375.
Risk Information: These procedures require needle access, possibly resulting in discomfort, tenderness, bruising, swelling, bleeding or pain at the access site, at which there is a small risk of infection. Lightheadedness, fainting, nausea or vomiting may occur. Before any medical procedure, review prescription and nonprescription medications and any natural or herbal remedies your patient is taking or plans to take.